Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

January 09, 2001; 56 (1) Articles

Welding-related parkinsonism

Clinical features, treatment, and pathophysiology

B. A. Racette, L. McGee-Minnich, S. M. Moerlein, J. W. Mink, T. O. Videen, J. S. Perlmutter
First published January 9, 2001, DOI: https://doi.org/10.1212/WNL.56.1.8
B. A. Racette
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. McGee-Minnich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. M. Moerlein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. W. Mink
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. O. Videen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. S. Perlmutter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Welding-related parkinsonism
Clinical features, treatment, and pathophysiology
B. A. Racette, L. McGee-Minnich, S. M. Moerlein, J. W. Mink, T. O. Videen, J. S. Perlmutter
Neurology Jan 2001, 56 (1) 8-13; DOI: 10.1212/WNL.56.1.8

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
10348

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Objective: To determine whether welding-related parkinsonism differs from idiopathic PD. Background: Welding is considered a cause of parkinsonism, but little information is available about the clinical features exhibited by patients or whether this is a distinct disorder. Methods: The authors performed a case-control study that compared the clinical features of 15 career welders, who were ascertained through an academic movement disorders center and compared to two control groups with idiopathic PD. One control group was ascertained sequentially to compare the frequency of clinical features, and the second control group was sex- and age-matched to compare the frequency of motor fluctuations. Results: Welders were exposed to a mean of 47,144 welding hours. Welders had a younger age at onset (46 years) of PD compared with sequentially ascertained controls (63 years; p < 0.0001). There was no difference in frequency of tremor, bradykinesia, rigidity, asymmetric onset, postural instability, family history, clinical depression, dementia, or drug-induced psychosis between the welders and the two control groups. All treated welders responded to levodopa. Motor fluctuations and dyskinesias occurred at a similar frequency in welders and the two control groups. PET with 6-[18F]fluorodopa obtained in two of the welders showed findings typical of idiopathic PD, with greatest loss in posterior putamen. Conclusions: Parkinsonism in welders is distinguished clinically only by age at onset, suggesting welding may be a risk factor for PD. These preliminary data cannot exclude a genetic contribution to susceptibility in these exposed individuals.

Welding is the process of joining metals by electric arc or flame with a filler material.1 The filler material, also called the consumable, is usually a coated electrode or wire that contributes metal to the joint. The four most common welds are the tungsten inert gas (TIG), metal inert gas (MIG), metal active gas (MAG), and manual metal arc (MMA).2 The process of melting the parent metal and the consumable produces concentrated particulate fumes and gases; the consumable produces 80 to 95% of the fume. These fumes contain a number of elements, including F, Mn, Zn, Pb, As, Ca, S, Cr, and Ni. Gases released include CO, CO2, F, and HF.3,4⇓

A number of health problems are attributed to welding fumes. Welding may cause acute upper respiratory symptoms,5 pulmonary edema,6 pulmonary fibrosis,7 and lung cancer.8 Welding has also been associated with genitourinary9 and laryngeal10 cancers. Actinic keratoconjuctivitis (welder’s flash)11 and cataract formation12 from ultraviolet radiation may be produced by the arc if eye protection is not worn. Neurologic complications of welding exposures include encephalopathy, probably from exposure to the fume (fume fever),13 and lead poisoning caused by heating lead-based paint.14

The materials safety data sheet (MSDS) for welding consumables lists parkinsonism as a potential hazard of welding. Evidence supporting these claims consists of several case reports15-18⇓⇓⇓; however, no established relationship between welding exposure and development of symptoms has been shown. Most reported patients had atypical features, including cognitive abnormalities, disturbances of sleep, peripheral nerve complaints, and mild motor slowing.15,19⇓ Manganese may be the toxic agent in welding fumes,19,20⇓ but welders exposed to manganese fumes in one study did not have higher blood concentrations of manganese than controls.19 We have studied welders who developed parkinsonism to determine whether the symptoms and disease course in these individuals were different from those in controls with idiopathic PD.

Methods.

We identified 15 career welders with parkinsonism from the Movement Disorders Center at Washington University School of Medicine (St. Louis, MO) from a group of 953 new parkinsonian patients seen between 1996 and 2000. Each welder reported the average number of hours per day worked, the years worked, exposure before symptom onset, and the percentage of time spent welding. We calculated cumulative hours of welding exposure before symptom onset (cumulative exposure = hours worked per week × days worked per year × years welding × fraction of working hours spent welding). History was taken and physical examination performed in all patients. We defined disease severity with the modified Hoehn and Yahr scale21 at the most recent rating; positive family history as having one or more first- or second-degree relatives with a history of parkinsonism; dementia as previously described,22 depression as that requiring treatment, psychosis as one or more episodes of visual or auditory hallucinations; asymmetry was determined by examination.

The first control group of 100 patients diagnosed with idiopathic PD23 was sequentially ascertained from the Movement Disorders Center. The second control group from the same center included six patients with PD age- and gender-matched to each of the welders with parkinsonism.

Statistical analysis.

Age at onset in the two groups and duration of disease was compared with a two-tailed, un-paired Student’s t-test. The distributions of the Hoehn and Yahr in the three groups were compared using a Mann–Whitney U test. We used a χ2 analysis to compare the frequency of individual clinical features between controls and welders. The Bonferroni correction was applied to correct for multiple comparisons; all p values obtained from comparison of clinical features were multiplied by 12, corresponding to the number of comparisons made between the welders and two control groups. All p values reported are corrected values.

6-[18F]fluorodopa ([18F]FDOPA) PET studies.

[18F]FDOPA PET scans were performed in two welders (aged 44 and 46 years at time of scan) and in 13 subjects (mean age, 49 years; range, 41 to 55 years) with typical idiopathic PD. These “control” subjects with PD had an average duration of symptoms of 2 years, closely matching the two welders. Similarly, they had asymmetric symptoms including bradykinesia, rigidity, and resting tremor (only one did not have resting tremor). Patients fasted overnight, with no PD medications taken for 12 hours before the study. PET scans were acquired by using a Siemens/CTI 953B scanner (Knoxville, TN) in 3D mode.24 Each subject took carbidopa 200 mg 1 to 2 hours before the study. A lateral skull radiograph recorded the position of each subject’s skull with respect to the PET images.25 Attenuation factors were measured by using a transmission scan made with rotating rod sources of 68Ge. [18F]FDOPA was prepared as previously reported.26 After injection of [18F]FDOPA (4.65 to 5.00 mCi with a specific activity of approximately 365 Ci/mol), we collected 30 sequential PET images, beginning with 2-minute frames and increasing to 5 minutes. Reconstructed resolution of the images was approximately 5 mm full width at half maximum in the transverse plane. All frames were realigned to correct for head movement during the study, with reference to the first frame in which counts filled the brain. Each sequential frame was aligned to its preceding frame by use of automatic image registration.27 Before alignment, frames were resampled to remove bias caused by pixelization.28 Resampled frames were then smoothed (by AIR, 5-mm 3D blur) and the mean bidirectional fit was computed. Each frame was resliced exactly once by use of the combination of transformation matrices of all preceding frames plus the inverse of the resampling matrix.

Regions of interest, including caudate (10 × 10 × 13.5 mm), anterior putamen (10 × 10 × 13.5 mm), posterior putamen (10 × 10 × 13.5 mm), and occipital region (27 × 13 × 4.5 mm), were identified by a blinded rater who used a stereotactic method independent of the appearance of the images.25 The striatal regions included four contiguous PET slices. An influx constant Ki was calculated,29,30⇓ with the occipital region as the input. We calculated Ki by using data from 24 to 94 minutes after injection. These PET studies were approved by the Human Studies committee and the radioactive drug research committee of Washington University School of Medicine. All participants gave written informed consent.

Results.

All welders were men, whereas our sequentially ascertained controls were 52 men and 48 women. The welders identified welding as a substantial occupational time commitment and had an average cumulative exposure of 47,144 welding hours. Welders were younger at symptom onset (46 years; range 29 to 68) compared with sequentially ascertained controls (63 years; range, 30 to 81; p < 0.0001) who had a typical age at onset.31 Duration of disease was 8.5 years in the welders, 6.6 years in sequentially ascertained controls, and 9.5 years in age-matched controls; the differences between the welders and these two control groups was not significant. Disease severities, as measured by the modified Hoehn and Yahr scale, were similar when comparing the welders to each of the control groups (Mann–Whitney U test; welders versus sequential controls: p = 0.15; welders versus age-matched controls: p = 0.12). The clinical features of the welders are summarized in table 1.

View this table:
  • View inline
  • View popup
Table 1.

Clinical features of 15 welders with parkinsonism

Family history was positive in 53% of welders, 32% of the sequentially ascertained controls, and 41% of age-matched controls (welders versus sequential controls, p = 0.11; and welders versus age-matched controls: p = 0.33). There was no significant difference between the frequency of cardinal PD signs when comparing welders with the two control groups ( table 2). There was a trend toward a greater frequency of tremor when comparing the age-matched controls with the welders, but this difference was not significant when correcting for multiple comparisons.

View this table:
  • View inline
  • View popup
Table 2.

Frequency of cardinal PD features

Thirteen welders experienced symptomatic improvement with levodopa therapy. One subject had adequate control of his symptoms with pramipexole monotherapy. Another subject was lost to follow-up and at the time of his last visit did not require symptomatic treatment. There was no significant difference between the frequency of motor fluctuations and dyskinesias when comparing the welders with the two control groups. There was a trend toward a greater frequency of motor fluctuations in age-matched controls compared with welders, but this difference was not significant after correcting for multiple comparisons. There was no significant difference between the frequency of clinical depression, dementia, or psychosis comparing the welders with the two control groups ( table 3).

View this table:
  • View inline
  • View popup
Table 3.

Frequency of complications of therapy

Eight welders had T1- and T2-weighted MRI scans of the brain; seven were normal, and one 78-year-old welder (Welder 15) had nonspecific white matter changes on T2-weighted images. [18F]FDOPA PET obtained in two of the welders (Welders 6 and 7) showed findings typical of idiopathic PD with asymmetrically reduced striatal uptake, with greatest loss of uptake in posterior putamen ( table 4). Although limited to only two welders, the degree of [18F]FDOPA PET asymmetry in putamen corresponded with the degree of clinical asymmetry. Welder 6 had greater asymmetry of [18F]FDOPA PET uptake compared with Welder 7. The degree of clinical asymmetry was defined by comparing the left and right scores for bradykinesia, rigidity, and tremor on the motor subscale of the Unified PD Rating Scale (UPDRS)21 (maximum score = 32 on each side). Welder 6 had motor subscale scores of 7 versus 1, compared with Welder 7, who had motor subscale scores of 10.5 versus 5.

View this table:
  • View inline
  • View popup
Table 4.

Findings in 6-[18F]fluorodopa PET studies

Discussion.

Parkinsonism associated with welding is not clinically different from idiopathic PD, with the exception of a younger age at onset. Comparison of 15 welders with sequentially ascertained controls with idiopathic PD showed no significant differences except for younger age at onset. Subsequent comparisons of the welders with age-matched controls showed no significant differences. We found a high prevalence of familial PD in the welders and controls; this is likely due to the inclusion of second-degree relatives with PD in our definition of familial PD. There was no preponderance of psychosis, dementia, or clinical depression to suggest a predisposition to neuropsychiatric symptoms, as described previously.32 Furthermore, levodopa provided similar benefits in welders, and they developed typical motor fluctuations after long-term treatment.

Our clinical observations and PET findings suggest that the pathophysiology of welding-related parkinsonism is similar to idiopathic PD, but we do not have pathologic confirmation of the diagnoses. Nevertheless, we speculate that the younger age at onset may be attributable to the effects of an accelerating agent from welding in a potentially “at-risk” patient who might otherwise develop PD with a later age at onset. Alternatively, parkin-associated parkinsonism could cause this phenotype in either familial or sporadic young-onset parkinsonism.33 Expression of a genetic parkinsonism could be mediated by an environmental modifier. If welding contributes to the parkinsonism in these patients, presumably the accelerant would be inhaled, and the element in the inhalant most consistently associated with an extrapyramidal syndrome is manganese.

A variety of occupational manganese exposures are associated with a primarily extrapyramidal presentation called manganism.34-38⇓⇓⇓⇓ The syndrome, best characterized in Moroccan manganese miners, includes progressive parkinsonism, dystonia, and neuropsychiatric symptoms.34 Those exposed to manganese while working in the steel industry also may develop progressive parkinsonism.35-37⇓⇓ Levodopa responsiveness in these parkinsonian subjects is transient and not associated with motor fluctuations.39-41⇓⇓ Although our patients differ from the classic scenario of manganese exposures, this does not necessarily disprove the association. It is possible that our patients experienced a lower level of inhaled manganese exposure compared with occupations involving crushing of manganese ore (miners), because ore crushing produces higher air concentrations of manganese.16 Low-level, long-term exposure over many years may be more analogous to unknown environmental triggers hypothesized to cause PD.42

Our two welders who had PET had asymmetric reduction of striatal [18F]FDOPA uptake with greater reduction of uptake in posterior putamen, findings that are typical of idiopathic PD.43 Although there are only two subjects, the welders did have greater asymmetry of caudate [18F]FDOPA uptake than our 13 subjects with PD. An older study found normal striatal [18F]FDOPA uptake in people with manganism; however, because of the relatively low resolution of the PET scanner in that study, the authors were only able to calculate uptake in left and right striatum and could not identify specific reductions in smaller regions such as posterior putamen.44,45⇓ It is also not clear whether the four subjects in that study had clinical manifestations similar to ours. They did report that all had bradykinesia, rigidity, and “gait abnormalities.” Two had mild rest tremor, but the degree of asymmetry and response to levodopa were not addressed,46 making it difficult to directly compare our results. Typical manganism may cause characteristic symmetric hyperintensities in the globus pallidus on T1-weighted MRI that resolve when the exposure is eliminated.15,45,47,48⇓⇓⇓ However, the sensitivity of the T1 signal changes for manganism is unknown. None of our welders had MRI-identified abnormalities in the basal ganglia, but the PET studies provided results typical of idiopathic PD. These findings suggest that our welders have a pathologic condition similar to idiopathic PD.

Our study suggests that welding may be a risk factor for a parkinsonism syndrome that is associated with reduced [18F]FDOPA uptake and is clinically indistinguishable from idiopathic PD except for age at onset. We believe that welding exposure acts as an accelerant to cause PD. Our findings do not prove that manganese is the toxic agent, and other components of the fume could be responsible for parkinsonism in welders. Further studies are necessary to clarify this important issue. A detailed clinical evaluation of career welders compared with age-matched controls in a proper epidemiologic study will be essential to prove the relationship between welding and parkinsonism. If further studies prove an increased risk of parkinsonism in welders, welding may be the first example of an environmental risk factor for idiopathic PD.

Acknowledgments

Supported by NIH grants NS31001 and NS01808, the American Parkinson’s Disease Association, the Clinical Hypotheses Research Section of the Charles A. Dana Foundation, and the McDonnell Center for the Study of Higher Brain Function.

Acknowledgment

The authors thank John Hood, Jr., and Terry Anderson for expert technical assistance, William H. Margenau and David C. Ficke for radioisotope production, and Dr. Tamara Hershey for statistical assistance.

Footnotes

  • See also page 4

  • Received April 3, 2000.
  • Accepted September 10, 2000.

References

  1. ↵
    Wallace ME, Fischbach T, Kovein RJ. Occupational Safety and Health Administration. In-depth survey report. Control technology assessment for the Welding Operations Boilermaker’s National Apprenticeship Training School, Kansas City, KS. June 27, 1997. No. ECTB 214–13a.
  2. ↵
    Hemminki K, Peto J, Stern RM. Summary report: international conference on health hazards and biological effects of welding fumes and gases. In: Stern RM, Berlin A, Fletcher AC, Jarvisalo J, eds. Health hazards and biologic effects of welding fumes and gases. Amsterdam, the Netherlands: Excerpta Medica, 1986: 1–5.
  3. ↵
    National Institute of Occupational Safety and Health. Criteria for a recommended standard: occupational exposure to welding, brazing, and thermal cutting. Cincinnati, OH: US Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, 1988. Division of Health and Human Services (NIOSH) Publication No. 88–110.
  4. ↵
    American Welding Society Safety and Health Committee. Effects of welding on health VIII. Miami, FL: American Welding Society, Safety and Health Committee, 1993. ISBN: 0–87171–437-X.
  5. ↵
    Papp JL. Metal fume fever. Postgrad Med . 1963; 43: 160–163.
  6. ↵
    Herbert A, Sterling G, Abraham J, Corrin B. Desquamative interstitial pneumonia in an aluminum welder. Hum Pathol . 1982; 13: 694–699.
    OpenUrlCrossRefPubMed
  7. ↵
    Meyer EC, Kratzinger SF, Miller WH. Pulmonary fibrosis in an arc welder. Arch Environ Health . 1967; 15: 462–469.
    OpenUrlPubMed
  8. ↵
    Sjogren B, Gustavsson A, Hedstrom L. Mortality in two cohorts of welders exposed to high- and low-levels of hexavalent chromium. Scand J Work Environ Health . 1987; 13: 247–251.
    OpenUrlCrossRefPubMed
  9. ↵
    Becker N, Claude J, Frentzel–Beyme R. Cancer risk of arc welders exposed to fumes containing chromium and nickel. Scand J Work Environ Health . 1985; 11: 75–82.
  10. ↵
    Olsen J Sabroe S, Lajer M. Welding and cancer of the larynx: a case-control study. Eur J Cancer Clin Oncol . 1984; 20: 639–643.
    OpenUrlCrossRefPubMed
  11. ↵
    Sykowski P. Dendritic type of keratitis caused by a welding arc. Am J Ophthalmol . 1951; 34: 99–100.
    OpenUrlPubMed
  12. ↵
    Palmer WG. Effects of welding on health IV. Miami, FL: American Welding Society, 1983: 37.
  13. ↵
    Johnson JS, Kilburn KH. Cadmium induced metal fume fever; results of inhalation challenge. Am J Ind Med . 1983; 4: 533–540.
    OpenUrlCrossRefPubMed
  14. ↵
    National Institute of Occupational Safety and Health Bulletin. Preventing lead poisoning in construction workers. NIOSH alert: April 1992. Division of Health and Human Services (NIOSH) Publication No. 91–116a.
  15. ↵
    Nelson K, Golnick J, Korn T, Angle C. Manganese encephalopathy: utility of early magnetic resonance imaging. Br J Ind Med . 1993; 50: 510–513.
    OpenUrlPubMed
  16. ↵
    Tanaka S, Lieben J. Manganese poisoning and exposure in Pennsylvania. Arch Environ Health . 1969; 19: 674–684.
    OpenUrlPubMed
  17. ↵
    Feldman RG. Manganese as possible ecoetiologic factor in Parkinson’s disease. Ann NY Acad Sci . 1992; 648: 266–267.
    OpenUrlCrossRefPubMed
  18. ↵
    Kim Y, Kim HW, Ito K, et al. Idiopathic parkinsonism with superimposed manganese exposure: utility of positron emission tomography. Neurotoxicology . 1999; 20: 249–252.
    OpenUrlPubMed
  19. ↵
    Sjogren B, Anders I, Frech W, et al. Effects on the nervous system among welders exposed to aluminum and manganese. Occup Environ Med . 1996; 53: 32–40.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Chandra SV, Shukla GS, Srivastava RS, Singh H, Gupta VP. An exploratory study of manganese exposure to welders. Clin Toxicol . 1981; 18: 407–416.
    OpenUrlPubMed
  21. ↵
    Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent developments in Parkinson’s disease. New York, NY: Macmillan, 1987: 153–163.
  22. ↵
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (DSM-IV). Washington, DC: American Psychiatric Association 1994; 143–147.
  23. ↵
    Racette BA, Rundle M, Parsian A, Perlmutter JS. Evaluation of a screening questionnaire for genetic studies of Parkinson’s disease. Am J Med Genet . 1999; 88: 539–543.
    OpenUrlCrossRefPubMed
  24. ↵
    Spinks TJ, Jones T, Bailey DL, et al. Physical performance of a positron tomograph for brain imaging with retractable septa. Phys Med Biol . 1992; 37: 1637–1655.
    OpenUrlCrossRefPubMed
  25. ↵
    Fox PT, Perlmutter JS, Raichle ME. A stereotactic method of anatomical localization for positron emission tomography. J Comput Assist Tomogr . 1985; 9: l4l–l53.
    OpenUrl
  26. ↵
    Moerlein SM, Verrant JA, Bellamy JA, Perlmutter JS, Welch MJ. Optimized clinical production of the PET tracer 6-[F-18]fluorodopa. Int Pharm Abst . 1999; 36: 2269.Abstract.
  27. ↵
    Woods RP, Cherry SR, Mazziotta JC. Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr . 1992; 16: 620–633.
    OpenUrlCrossRefPubMed
  28. ↵
    Andersson JLR. How to obtain high-accuracy image registration: application to movement correction of dynamic positron emission tomography data. Eur J Nucl Med . 1998; 25: 575–586.
    OpenUrlPubMed
  29. ↵
    Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab . 1983; 3: 1–7.
    OpenUrlCrossRefPubMed
  30. ↵
    Logan J, Wolf AP, Shiue C-Y, Fowler JS. Kinetic modeling of receptor-ligand binding applied to positron emission tomographic studies with neuroleptic tracers. J Neurochem . 1987; 48: 73–83.
    OpenUrlCrossRefPubMed
  31. ↵
    Parkinson Study Group. DATATOP: a multicenter controlled trial in early Parkinson’s disease. Arch Neurol . 1989; 46: 1052–1060.
    OpenUrlCrossRefPubMed
  32. ↵
    Sjogren B, Gustavsson P, Hogstedt C. Neuropsychiatric symptoms among welders exposed to neurotoxic metals. Br J Ind Med . 1990; 47: 704–707.
    OpenUrlPubMed
  33. ↵
    Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson’s disease and mutations in the Parkin gene. N Engl J Med . 2000; 342: 1560–1567.
    OpenUrlCrossRefPubMed
  34. ↵
    Rodier J. Manganese poisoning in Moroccan miners. Br J Ind Med . 1955; 12: 21–35.
    OpenUrlPubMed
  35. ↵
    Cook DG, Fahn S, Brait KA. Chronic manganese intoxication. Arch Neurol . 1974; 30: 59–64.
    OpenUrlCrossRefPubMed
  36. ↵
    Whitlock CM, Amuso SJ, Bittenbender JB. Chronic neurological disease in two manganese steel workers. Am Ind Hyg Assoc J . 1966; 454–459.
  37. ↵
    Wang JD, Huang CC, Hwang YH, Chiang JR, Lin JM, Chen JS. Manganese induced parkinsonism: an outbreak due to an unrepaired ventilation control system in a ferromanganese smelter. Br J Ind Med . 1989; 46: 856–859.
    OpenUrlPubMed
  38. ↵
    Calne DB, Chu NS, Huang CC, Lu CS, Olanow W. Manganism and idiopathic Parkinsonism: similarities and differences. Neurology . 1994; 44: 1583–1586.
    OpenUrlFREE Full Text
  39. ↵
    Huang CC, Lu CS, Chu NS, et al. Progression after chronic manganese exposure. Neurology . 1993; 43: 1479–1483.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Lu CS, Chin–Chang H, Chu NS, Calne DB. Levodopa failure in chronic manganism. Neurology . 1994; 44: 1600–1602.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Mena I, Court J, Fuenzalida S, Papavasiliou PS, Cotzias GC. Modification of chronic manganese poisoning: treatment with L-dopa or 5-OH tryptophane. N Engl J Med . 1970; 282: 5–10.
  42. ↵
    Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA . 1999; 281: 341–346.
    OpenUrlCrossRefPubMed
  43. ↵
    Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol . 1990; 28: 547–555.
    OpenUrlCrossRefPubMed
  44. ↵
    Wolters EC, Huang CC, Clark C, et al. Positron emission tomography in manganese intoxication. Ann Neurol . 1989; 26: 647–651.
    OpenUrlCrossRefPubMed
  45. ↵
    Eriksson H, Tedroff J, Thuomas KA, et al. Manganese induced brain lesions in Macaca fascicularis as revealed by positron emission tomography and magnetic resonance imaging. Arch Toxicol . 1992; 66: 403–407.
    OpenUrlCrossRefPubMed
  46. ↵
    Mena I, Court J, Fuenzalida S, Papavasilou PS, Cotzias GC. Chronic manganese poisoning: clinical picture and manganese turnover. Neurology . 1967; 17: 128–136.
    OpenUrlFREE Full Text
  47. ↵
    Shinotoh H, Snow BJ, Hewitt KA, et al. MRI and PET studies of manganese-intoxicated monkeys. Neurology . 1995; 45: 1199–1204.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    Mirowitz SA, Westrich TJ, Hirgsch JD. Hyperintense basal ganglia on T1-weighted MR images in patients receiving parenteral nutrition. Radiology . 1991; 181: 117–120.
    OpenUrlPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Methods.
    • Results.
    • Discussion.
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Brain Metabolism Related to Mild Cognitive Impairment and Phenoconversion in Patients With Isolated REM Sleep Behavior Disorder

Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu

► Watch

Related Articles

  • Environmental toxins accelerate Parkinson’s disease onset

Topics Discussed

  • All Toxicology
  • All Movement Disorders
  • Parkinson's disease/Parkinsonism

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Articles
    Reduced uptake of [18F]FDOPA PET in asymptomatic welders with occupational manganese exposure
    S.R. Criswell, J.S. Perlmutter, T.O. Videen et al.
    Neurology, April 06, 2011
  • Articles
    Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders
    B. A. Racette, S. D. Tabbal, D. Jennings et al.
    Neurology, January 24, 2005
  • Articles
    Dopaminergic function in patients with posttraumatic parkinsonism: An 18F-dopa PET study
    N. Turjanski, A. J. Lees, D. J. Brooks et al.
    Neurology, July 01, 1997
  • Editorials
    Welding and Parkinson disease
    Is there a bond?
    Karl Kieburtz, Roger Kurlan et al.
    Neurology, June 27, 2005
Neurology: 100 (21)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise